NotableLead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLCShow 4 more changesShow less
Primary endpoints: details revised at 4 of 6 entries
Study sites: 25 to 26
Eligibility criteria expanded, about 17 words
Secondary endpoints: details revised at 8 of 16 entries
MinorStudy sites: 23 to 25v11
MinorTrial sites expanded: 20 → 23 locationsv10
MinorRe-verified, no change to tracked fieldsv9
MinorStart date: Jul 2, 2026 to Jul 6, 2026v8
MinorStudy sites: 18 to 20v7
MinorStudy sites: 17 to 18v6
MinorTrial sites expanded: 14 → 17 locationsv5
NotableRecruitment opened
Trial sites expanded: 0 → 14 locations
Start date changed from estimate of Jul 28, 2026 to Jul 2, 2026
v4
NotableTrial status: Not Yet Recruiting to Recruiting
Study sites: 0 to 14
v3
MinorRe-verified, no change to tracked fieldsv2
MinorStudy First Submitted
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Researchers are looking for new ways to treat children with relapsed or refractory solid tumors:
* Relapsed means the cancer came back after treatment
* Refractory means the cancer did not respond (get smaller or go away) to treatment
* Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids
The study treatment I-DXd (also known as MK-2400 or ifinatamab deruxtecan) is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn:
* About the safety of I-DXd and if children younger than 12 years old tolerate it
* How many children who receive I-DXd have the cancer get smaller or go away